PTH-related protein, or ''PTHrP'', is a hormone which was discovered in 1987. As its name
implies, it is closely related to another hormone discovered in the 1920's named parathyroid
hormone or ''PTH''. PTH has been shown to be effective in treating osteoporosis in both
animals and humans. PTHrP has been shown to be effective in treating osteoporosis in
laboratory animals, and there are strong scientific reasons to think that it may be
effective in humans as well. However, no human trials with PTHrP in the treatment of
osteoporosis have been performed. The studies in this trial are focussed on determining
whether PTHrP can indeed increase bone mass in postmenopausal women with osteoporosis, when
administered daily by subcutaneous injection for three months.
- Healthy caucasian postmenopausal females between 50-75 years of age with low bone
mineral density at the lumbar spine or hip as measured using dual energy x-ray
absorptiometry or DXA.
- ON estrogen replacement treatment for at least three years.
- Heart, vascular, kidney, liver, lung, hormonal, musculo-skeletal disease (other than
osteoporosis), rheumatic, blood diseases are exclusion criteria.
- High blood pressure
- Alcohol or drug dependence
- Prior use of a drug treatment for osteoporosis such as PTH, bisphosphonates,
raloxifene, or calcitonin within the preceding five years